MedPath
FDA Approval

Omnipaque

FDA-approved pharmaceutical product with comprehensive regulatory information, manufacturing details, and complete labeling documentation.

FDA Approval Summary

Company
GE Healthcare Inc.
DUNS: 053046579
Effective Date
April 25, 2023
Labeling Type
HUMAN PRESCRIPTION DRUG LABEL
Iohexol(350 mg in 1 mL)

Manufacturing Establishments3

FDA-registered manufacturing facilities and establishments involved in the production, packaging, or distribution of this drug product.

GE Healthcare Lindesnes

GE Healthcare Inc.

518890970

GE Healthcare Ireland Limited

GE Healthcare Inc.

988006565

GE Healthcare Shanghai Co., Ltd.

GE Healthcare Inc.

545292716

Products2

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Omnipaque

Product Details

NDC Product Code
0407-1414
Application Number
NDA020608
Marketing Category
NDA (C73594)
Route of Administration
INTRAVENOUS, INTRAVASCULAR, ORAL, RECTAL
Effective Date
April 25, 2023
TROMETHAMINEInactive
Code: 023C2WHX2VClass: IACT
EDETATE CALCIUM DISODIUMInactive
Code: 25IH6R4SGFClass: IACT
HYDROCHLORIC ACIDInactive
Code: QTT17582CBClass: IACT
IohexolActive
Code: 4419T9MX03Class: ACTIRQuantity: 350 mg in 1 mL

Omnipaque

Product Details

NDC Product Code
0407-1413
Application Number
NDA020608
Marketing Category
NDA (C73594)
Route of Administration
INTRAVENOUS, INTRAVASCULAR, INTRATHECAL, ORAL, RECTAL
Effective Date
April 25, 2023
HYDROCHLORIC ACIDInactive
Code: QTT17582CBClass: IACT
TROMETHAMINEInactive
Code: 023C2WHX2VClass: IACT
EDETATE CALCIUM DISODIUMInactive
Code: 25IH6R4SGFClass: IACT
IohexolActive
Code: 4419T9MX03Class: ACTIRQuantity: 300 mg in 1 mL
© Copyright 2025. All Rights Reserved by MedPath